JP2001511149A5 - - Google Patents

Download PDF

Info

Publication number
JP2001511149A5
JP2001511149A5 JP1998533114A JP53311498A JP2001511149A5 JP 2001511149 A5 JP2001511149 A5 JP 2001511149A5 JP 1998533114 A JP1998533114 A JP 1998533114A JP 53311498 A JP53311498 A JP 53311498A JP 2001511149 A5 JP2001511149 A5 JP 2001511149A5
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP1998533114A
Other languages
English (en)
Japanese (ja)
Other versions
JP2001511149A (ja
Filing date
Publication date
Priority claimed from US08/791,391 external-priority patent/US6590079B2/en
Application filed filed Critical
Publication of JP2001511149A publication Critical patent/JP2001511149A/ja
Publication of JP2001511149A5 publication Critical patent/JP2001511149A5/ja
Ceased legal-status Critical Current

Links

JP53311498A 1997-01-30 1998-01-30 抗αvβ3組換えヒト化抗体、これをコードする核酸、および使用の方法 Ceased JP2001511149A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/791,391 1997-01-30
US08/791,391 US6590079B2 (en) 1997-01-30 1997-01-30 Anti-αvβ3 recombinant human antibodies, nucleic acids encoding same
PCT/US1998/001826 WO1998033919A2 (en) 1997-01-30 1998-01-30 Anti-alpha-v beta-3 recombinant humanized antibodies, nucleic acids encoding same and methods of use

Publications (2)

Publication Number Publication Date
JP2001511149A JP2001511149A (ja) 2001-08-07
JP2001511149A5 true JP2001511149A5 (enExample) 2005-10-06

Family

ID=25153592

Family Applications (1)

Application Number Title Priority Date Filing Date
JP53311498A Ceased JP2001511149A (ja) 1997-01-30 1998-01-30 抗αvβ3組換えヒト化抗体、これをコードする核酸、および使用の方法

Country Status (6)

Country Link
US (2) US6590079B2 (enExample)
EP (1) EP0970217A2 (enExample)
JP (1) JP2001511149A (enExample)
AU (1) AU737569B2 (enExample)
CA (1) CA2278848A1 (enExample)
WO (1) WO1998033919A2 (enExample)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6590079B2 (en) * 1997-01-30 2003-07-08 Ixsys, Incorporated Anti-αvβ3 recombinant human antibodies, nucleic acids encoding same
US20010011125A1 (en) * 1997-01-30 2001-08-02 William D. Huse Anti-alpha v beta 3 recombinant human antibodies, nucleic acids encoding same and methods of use
US6596850B1 (en) * 1998-01-30 2003-07-22 Ixsys, Incorporated Anti-αv3β3 recombinant human antibodies, nucleic acids encoding same
EP1135688A2 (en) * 1998-12-04 2001-09-26 Novartis AG Methods and compositions useful for targeting activated vitronectin receptor alpha(nu)-beta(3)
US6521593B1 (en) * 1999-02-01 2003-02-18 Childrens Hospital Los Angeles Methods for inhibiting brain tumor growth
US6531580B1 (en) * 1999-06-24 2003-03-11 Ixsys, Inc. Anti-αvβ3 recombinant human antibodies and nucleic acids encoding same
WO2001024827A2 (en) * 1999-10-06 2001-04-12 Basf Aktiengesellschaft INHIBITORS OF THE ENDOTHELIN SIGNALLING PATHWAY AND αVβ3 INTEGRIN RECEPTOR ANTAGONISTS FOR COMBINATION THERAPY
US7229619B1 (en) 2000-11-28 2007-06-12 Medimmune, Inc. Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
AU2001238079A1 (en) * 2000-02-09 2001-08-20 Med Immune, Inc. Antibody gene therapy with adeno-associated viral vectors
EP2341074A1 (en) * 2000-03-01 2011-07-06 MedImmune, LLC Antibodies binding to the f protein of a respiratory syncytial virus (rsv)
US6855493B2 (en) 2000-11-28 2005-02-15 Medimmune, Inc. Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
US7179900B2 (en) 2000-11-28 2007-02-20 Medimmune, Inc. Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
PT1355919E (pt) 2000-12-12 2011-03-02 Medimmune Llc Moléculas com semivida longa, composições que as contêm e suas utilizações
AU2002306651B2 (en) * 2001-03-02 2007-12-13 Medimmune, Llc Methods of preventing or treating inflammatory or autoimmune disorders by administering integrin alphav Beta3 antagonists
AU2002316855B2 (en) * 2001-04-24 2008-03-13 Merck Patent Gmbh Combination therapy using anti-angiogenic agents and TNFalpha
KR20050032507A (ko) * 2001-10-10 2005-04-07 파마시아 이탈리아 에스.피.에이. 스테로이드 화합물을 이용한 골소실의 예방 및 치료 방법
US7365167B2 (en) 2001-11-26 2008-04-29 Cell Matrix, Inc. Humanized collagen antibodies and related methods
US7390885B2 (en) * 2001-11-26 2008-06-24 Cell Matrix, Inc. Humanized collagen antibodies and related methods
CA2478239A1 (en) * 2002-03-04 2003-09-18 Medimmune, Inc. The prevention or treatment of cancer using integrin alphavbeta3 antagonists in combination with other agents
CA2478317A1 (en) * 2002-03-04 2003-09-18 Medimmune, Inc. Methods of preventing or treating disorders by administering an integrin .alpha.v.beta.3 antagonist in combination with an hmg-coa reductase inhibitor or a bisphosphonate
CA2488441C (en) * 2002-06-03 2015-01-27 Genentech, Inc. Synthetic antibody phage libraries
US7132100B2 (en) 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
CA2512174A1 (en) * 2003-01-30 2004-08-12 Christian B. Allan Anti-integrin .alpha..nu..beta.3 antibody formulations and uses thereof
WO2004066956A2 (en) * 2003-01-30 2004-08-12 Medimmune, Inc. Uses of integrin alphavbeta3 antagonists
US20040208869A1 (en) * 2003-01-30 2004-10-21 Medimmune, Inc. Uses of anti-integrin alphanubeta3 antibody formulations
GB0302699D0 (en) * 2003-02-06 2003-03-12 Univ Bradford Immunoglobulin
AU2004229501B2 (en) 2003-04-11 2011-08-18 Medimmune, Llc Recombinant IL-9 antibodies and uses thereof
US7351739B2 (en) 2004-04-30 2008-04-01 Wellgen, Inc. Bioactive compounds and methods of uses thereof
ATE461708T1 (de) * 2004-05-07 2010-04-15 Univ North Carolina Verfahren zur verstärkung oder hemmung des insulinähnlichen wachstumsfaktors-i
US8187595B2 (en) * 2004-05-07 2012-05-29 The University Of North Carolina At Chapel Hill Monoclonal antibodies for enhancing or inhibiting insulin-like growth factor-I
AU2005277567A1 (en) * 2004-08-16 2006-03-02 Medimmune, Llc Integrin antagonists with enhanced antibody dependent cell-mediated cytotoxicity activity
US20060121042A1 (en) 2004-10-27 2006-06-08 Medimmune, Inc. Modulation of antibody specificity by tailoring the affinity to cognate antigens
CA2585104A1 (en) 2004-12-06 2006-06-15 Kirin Beer Kabushiki Kaisha Human monoclonal antibodies to influenza m2 protein and methods of making and using same
CA2611519A1 (en) 2005-06-17 2006-12-28 Tolerx, Inc. Ilt3 binding molecules and uses therefor
WO2007002543A2 (en) 2005-06-23 2007-01-04 Medimmune, Inc. Antibody formulations having optimized aggregation and fragmentation profiles
WO2008094176A2 (en) * 2006-06-19 2008-08-07 Tolerx, Inc. Ilt3 binding molecules and uses therefor
AU2007272970C1 (en) 2006-07-11 2013-01-10 Roy C. Levitt Rhinosinusitis prevention and therapy with proinflammatory cytokine inhibitors
CA2660519A1 (en) 2006-08-10 2008-02-21 Roy C. Levitt Localized therapy of lower airways inflammatory disorders with proinflammatory cytokine inhibitors
WO2008048545A2 (en) 2006-10-16 2008-04-24 Medimmune, Llc. Molecules with reduced half-lives, compositions and uses thereof
US20100197896A1 (en) * 2007-05-16 2010-08-05 Leung Shui-On Functional humanization of complementarity determining regions (cdrs)
EP1997830A1 (en) 2007-06-01 2008-12-03 AIMM Therapeutics B.V. RSV specific binding molecules and means for producing them
US8633139B2 (en) 2007-12-21 2014-01-21 Abbvie Biotherapeutics Inc. Methods of screening complex protein libraries to identify altered properties
NZ589795A (en) 2008-06-16 2013-02-22 Patrys Ltd Use of LM-1 antibody which binds to NONO/nmt55 protein to prevent metastasis
US20120134984A1 (en) 2009-06-01 2012-05-31 Olga Lubman Molecules with extended half-lives and uses thereof
US8568726B2 (en) 2009-10-06 2013-10-29 Medimmune Limited RSV specific binding molecule
AU2013206788B2 (en) 2011-12-28 2017-11-30 Immunoqure Ag Method of providing monoclonal auto-antibodies with desired specificity
EP2890716A4 (en) 2012-08-31 2016-06-08 Univ North Carolina MONOCLONAL ANTIBODIES FOR THE REINFORCEMENT OR INHIBITION OF INSULINARY FACTOR 1 (IGF-1)
EP4056591A1 (en) 2013-07-03 2022-09-14 ImmunoQure AG Human anti-ifn-alpha antibodies
AU2018243670B2 (en) 2017-03-31 2025-05-01 The Regents Of The University Of California Compositions and methods for targeting and killing ALPHA-V BETA-3-positive cancer stem cells (CSCs) and treating drug resistant cancers
KR102098462B1 (ko) * 2018-03-14 2020-04-08 가톨릭대학교 산학협력단 αvβ3 인테그린 표적 단일 도메인 항체
US20230092787A1 (en) * 2020-02-17 2023-03-23 University Of Virginia Patent Foundation Car t cells targeting the integrin alphav beta3 exhibit robust anti-tumor responses against gliomas and other solid tumor malignancies

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5264563A (en) 1990-08-24 1993-11-23 Ixsys Inc. Process for synthesizing oligonucleotides with random codons
US5667988A (en) 1992-01-27 1997-09-16 The Scripps Research Institute Methods for producing antibody libraries using universal or randomized immunoglobulin light chains
DE69322860T2 (de) * 1992-04-03 1999-07-01 Genentech, Inc., South San Francisco, Calif. Antikörper gegen alpha v beta 3 integrin
IT1268004B1 (it) * 1994-02-02 1997-02-20 Giuseppe Lambertini Dispositivo per il bloccaggio di un pezzo su un piano d'appoggio, quale una tavola di macchina operatrice.
US5753230A (en) 1994-03-18 1998-05-19 The Scripps Research Institute Methods and compositions useful for inhibition of angiogenesis
CA2223885A1 (en) 1995-06-07 1996-12-19 Centocor, Inc. Platelet-specific chimeric immunoglobulin and methods of use therefor
US6590079B2 (en) 1997-01-30 2003-07-08 Ixsys, Incorporated Anti-αvβ3 recombinant human antibodies, nucleic acids encoding same
US6531580B1 (en) 1999-06-24 2003-03-11 Ixsys, Inc. Anti-αvβ3 recombinant human antibodies and nucleic acids encoding same

Similar Documents

Publication Publication Date Title
JP2000509637A5 (enExample)
JP2000509912A5 (enExample)
JP2000507042A5 (enExample)
JP2000509635A5 (enExample)
JP2000510751A5 (enExample)
JP2000509942A5 (enExample)
JP2000509587A5 (enExample)
JP2000507369A5 (enExample)
JP2000507433A5 (enExample)
JP2000508866A5 (enExample)
JP2000510793A5 (enExample)
JP2000508022A5 (enExample)
JP2000508841A5 (enExample)
JP2000508680A5 (enExample)
JP2000509804A5 (enExample)
JP2000509853A5 (enExample)
JP2000509755A5 (enExample)
JP2000510969A5 (enExample)
JP2000510247A5 (enExample)
JP2000508836A5 (enExample)
JP2000508102A5 (enExample)
JP2000509818A5 (enExample)
JP2000509520A5 (enExample)
JP2000507434A5 (enExample)
JP2000508880A5 (enExample)